Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|November 1, 2019
Avantor Technical Experts to Share Cell and Gene Therapy Production Insight at CPhI Worldwide 2019
Author(s)Pharmaceutical Technology Editors
Dr. Ger Brophy, executive vice president, Biopharma Production for Avantor, will deliver the keynote address at the conference and Claudia Berrón, senior vice president, Business Development and Commercial Operations for Avantor, will discuss on leveraging biopharma 4.0 to reconstruct the biopharma supply chain and manufacturing practices.
Advertisement
Avantor, a mission-critical products and services provider, announced its technical experts will be presenting their insights on biopharmaceutical and cell and gene therapy developments during the BioProduction Conference at CPhI Worldwide from Nov. 4–7 in Frankfurt, Germany.
According to an Oct. 31, 2019 press release, Dr. Ger Brophy, executive vice president, Biopharma Production for Avantor, will deliver the keynote address at the conference and Claudia Berrón, senior vice president, Business Development and Commercial Operations for Avantor, will discuss on leveraging biopharma 4.0 to reconstruct the biopharma supply chain and manufacturing practices.
"As it continuously evolves, the cell and gene therapy industry is adopting lessons learned from other bioprocessing disciplines in order to continue to advance processes,” said Brophy in the press release. “In addition, we are at a tipping point in our supply chain processes with biopharma 4.0 as a catalyst. The Internet of Things will touch and connect our workflows in ways that are yet to be determined.”
Avantor’s first session is titled “Evolution of Raw Material Development and Regulatory Standards – From Monoclonal Drugs to Cell & Gene Therapies” and will be located in the BioProduction Theater on Nov. 7 at 10:20 am. Its second session is titled “Digitalizing Biopharma: How Raw Material Data Can Maximize Biopharma Supply Chain and Manufacturing Practices” and will be located in Room Frequenz 1 on Nov. 7 from 3:00 to 3:30 pm.
The company will also be presenting at stand 120C26 in the BioProduction area at the event.
Source:
Advertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement